Elios Metastatic - Multi-Center Phase I/IIa Trial Of An Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (Ycwp) + Dendritic Cells (Dc) Vaccine In Addition To Standard Of Care Checkpoint Inhibitor Of Choice In Metastatic Melanoma Patients With Meas
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to (1) produce and test a vaccine that is made from your tumor cells and white blood cells to determine if it can be used in addition to the checkpoint inhibitor (CPI) that you are already taking to help fight your melanoma by producing a stronger immune response.
Criteria:
To Be Eligible: Patients Must Be 18+ Years Of Age With A Diagnosis Of Metastatic Melanoma, Nonpregnant And Nonbreastfeeding.
Keywords:
Melanoma, Cancer, Phase 1/2A, Phase I/Iia
For More Information:
Uc Cancer Center
(513) 584-7698
cancer@uchealth.com